People with severe sickle cell disease (SCD) have reported significant improvements in their quality of life after receiving the approved gene-editing therapy Casgevy (exagamglogene autotemcel).

81.7% of patients were on an SGLT2 inhibitor 74.7% of patients were on an ARNI 95.1% of patients were on a beta-blocker 83.1% of patients were on an MRA Despite high use of GDMT, the rate of ...

Correctsequence Therapeutics’ experimental gene-editing therapy CS-101 has been used to treat a person with sickle cell disease (SCD) for the first time. Prior to treatment with CS-101, the patient — ...

Welcome to the Modernize your code solution accelerator, designed to help customers transition their SQL queries to new environments quickly and efficiently. This accelerator is particularly useful ...

The expansion of the manufacturing infrastructure in Israel, which is being led by the Ministry of Defense Directorate for R&D (DDRD) (MAFAT), will allow production of infrared solutions for advanced ...

This project demonstrates a comprehensive data warehousing and analytics solution, from building a data warehouse to generating actionable insights. Designed as a portfolio project, it highlights ...